Search Results - M Frigault

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA by M. Frigault, S. Sher, J. Ravikrishnan, R. Izumi, J. Ware, H. Wong, A. Johnson, B. Stelte-Ludwig, J. Byrd, D. Sampath, K. Rogers, J. Woyach, R. Lapalombella, A. Hamdy

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma by Son Tran, Patrick Sipila, Melanie M. Frigault, Beatrix Stelte-Ludwig, Amy J. Johnson, Joseph Birkett, Raquel Izumi, Ahmed Hamdy, Ranjan Maity, Nizar J. Bahlis, Paola Neri, Aru Narendran

    Published in Blood Neoplasia (2025-02-01)
    Get full text
    Article


  3. 3

    Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study by Paolo Strati, Sven de Vos, Jia Ruan, Kami J. Maddocks, Christopher R. Flowers, Simon Rule, Priti Patel, Yan Xu, Helen Wei, Melanie M. Frigault, Roser Calvo, Martin J.S. Dyer

    Published in Haematologica (2021-07-01)
    Get full text
    Article


  4. 4

    Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia by Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps

    Published in Haematologica (2021-03-01)
    Get full text
    Article


  5. 5

    S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA by M. Dickinson, M. Kwon, J. Briones, U. Jäger, K. Kato, E. Bachy, D. Blaise, N. Boissel, N. Shah, M Frigault, P. Riedell, L. Shune, T. Teshima, X. Zhu, E. Orlando, L. Yi, J. Davis, E. Bleickardt, I. Flinn, P. Barba, P. Barba

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: